Jean Boulle Medtech Ltd. is active in a wide range
of medical technologies. JBM is an investor in early stage medical technologies, with a particular track record in the development of medical devices for use in cardiology.

Confidentiality and the protection of proprietary technologies limit the information that can be provided about JBM’s investments. Additional information will be made available as circumstances permit. JBM welcomes enquiries from those seeking financial and technical expertise to develop technologies that save lives or which improve quality of life.

For news on Jean Boulle Medtech Ltd. click here

tendyne-1

VDYNE LLC

Jean Boulle Medtech ("JBM") founded VDYNE, a medical device company focused on the development of a transcatheter replacement valve to treat patients suffering from tricuspid regurgitation (“TR”). TR occurs when the tricuspid valve is not functioning properly, and thereby fails to close.

The tricuspid valve separates the right atrium from the right ventricle and when the tricuspid valve does not close properly, blood flows backwards from the right ventricle into the right atrium instead of progressing to the heart for re-oxygenation. This "regurgitation" is a debilitating condition that impacts the general health and quality of life of approximately 5% of the elderly population. More importantly, surgical intervention to treat TR has high rates of mortality and morbidity, and there are presently no approved minimally-invasive valve replacement treatment alternatives.

JBM has assembled a strong and highly experienced team at VDYNE team, with a proven track-record in structural heart and the development of transcatheter therapies, including in the adjacent mitral valve replacement space. VDYNE is developing a unique technology with the ability to replace the existing dysfunctional tricuspid valve following delivery of a new prosthetic valve over a catheter (as opposed to open-heart surgery) and thereby reducing mortality rates and the related surgical complications. Importantly, the valve is designed to be completely repositionable and retrievable to enable precise placement by the physician.

VDYNE is currently undertaking late-stage pre-clinical testing, including the completion of good laboratory practice compliance and a range of mandatory pre-clinical testing steps. VDYNE raised $6.8m in Q4 2019 to fund the continued development of the valve.

VDYNE was the co-recipient of the Innovations in Cardiovascular Interventions & High-Tech Science Industry World Startup Competition 2020. The award is one of the world’s most significant and prestigious awards for medical interventions.

In January 2021 VDYNE closed a $21 million, heavily subscribed Series C financing. The financing was led by Jean Boulle Medtech and included both existing and new investors. The proceeds from the financing will be directed towards a programme of human clinical trials in the first half of 2021.  

TENDYNE HOLDINGS INC.

Jean Boulle Medtech was the founding investor of Tendyne Holdings, Inc. which developed one of the most promising Transcatheter mitral valve implant (“TMVI”) devices in existence today.

Implanted in a beating heart, the Tendyne™ valve enables a significantly less invasive procedure to mitral valve treatment than open heart surgery. Left untreated, mitral regurgitation can lead to heart failure and death. Tendyne™ undertook clinical trials in the United States, Great Britain and Australia as part of its multi-center global feasibility study on the safety and performance of the Tendyne™  valve in patients with symptomatic mitral regurgitation of degenerative or functional etiology, some of whose medical conditions would otherwise make them inoperable.  The valve was successfully tested in 2019 as part of a feasibility trial. In January 2020 the Tendyne™ valve received CE Mark approval from the European Union.

In September 2015 the Jean Boulle Group announced that Abbott Laboratories (NYSE: ABT) acquired Tendyne™ from Boulle Medtech and others for US$250 million in cash plus future payments tied to regulatory milestones. The remaining contracted milestone which are to be paid to Tendyne Holdings, Inc by Abbott Laboratories are US$50 million upon C.E Mark approval and US$100 million following F.D.A approval.

Structural heart conditions affect millions of adults and thousands of newborns each year[1],[2]. The structural heart medical device market represents the largest, fastest-growing cardiovascular device market opportunity today[3] and forecasted to be $10+ billion by 2025. The transcatheter mitral repair and replacement market alone is projected to grow from its current $400 million to a multi-billion dollar opportunity by 2025[4].

For more information, see www.tendyne.com

[1] Source: Micro Interventional Devices.
[2] Source: Abbott Laboratories Structural Heart Disease. Available https://www.sjm.com/en/professionals/disease-state-management/structural-heart-disease. Accessed March 2, 2018.
[3] Source: STRENGTH IN STRUCTURAL HEART April 11 2018
[4] Source: Based on analyst projections including current and future markets

HEAD OFFICE
25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

CALL US
Tel: +352 222 512
Fax: +352 222 413

Copyright © 2019 Jean Boulle Group. All rights reserved.